AstraZeneca PLC Q3 2023 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Christopher Winston Uhde - SEB, Research Division - Analyst : Can you hear me now?

Question: Christopher Winston Uhde - SEB, Research Division - Analyst : All right. Great. So my first question is for Sharon. Now that you taken over, I think we have a pretty good idea of what the strategy is for CVRM. Perhaps you could talk a little bit about what the R&I sort of big picture strategy is overall? And in terms of -- so R&D strategy and integrating that with commercial strategy and how to execute on it? And then my second question is on Farxiga. And maybe here, I'd like to start by congratulating Mene and his team, even though he's not here today, on the successful readout for zibotentan. I guess it's his brainchild and arguably the zenith of his achievements at AZ. But -- so a small percentage of patients that are eligible for SGLT2 actually get it across the each approved indication. Is the NRx split still even across the indicated patient groups? And how much gas is left in the tank in the U.S. and EU across those indications? We've got dapa, MI toplining positively, so how much impact can that have? And beyond it, are there any remaining steps you can take to convince prescribers or payers that a larger proportion of patients should be adding on SGLT2 on top of metformin or statin or BP meds or whatever before you start to bring Farxiga combos into the picture? So like -- the specific patient subgroups, for example? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. NOVEMBER 09, 2023 / 2:00PM, AZN.L - Q3 2023 AstraZeneca PLC Earnings Call And there's a logical follow-through. When the SGLT2s lose exclusivity, do you anticipate any substantial step-up in breadth of use? What might that look like? And does that impact how you view the opportunity for the novel Farxiga combo regimens like zibotentan?